Capstone Investment Advisors
PRTK

Capstone Investment Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Capstone Investment Advisors’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-12,900
Closed -$125K – 1387
2018
Q3 		$125K Sell
12,900
-33,700
-72% -$340K ﹤0.01% 1104
2018
Q2 		$475K Buy
+46,600
New +$527K 0.01% 485

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Capstone Investment Advisors's PRTK Position: Q4 2018 in Review

Capstone Investment Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2018, closing a stake of 12,900 shares — an estimated $125K sold.

Capstone Investment Advisors first reported a position in PRTK in Q2 2018 and held it in 2 quarters. The position peaked at $475K in Q2 2018. 102 funds tracked by Wall St. Rank hold PRTK as of Q4 2018.

  • Capstone Investment Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Capstone Investment Advisors sold 12,900 Paratek Pharmaceuticals, Inc. shares in Q4 2018, an estimated $125K.
  • Capstone Investment Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2018 and held it in 2 quarters.
  • Capstone Investment Advisors's Paratek Pharmaceuticals, Inc. position peaked at $475K in Q2 2018.
  • 102 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2018.

Based on Capstone Investment Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.